I do not think counting the FDA's first review team's apparent incompetence and reluctance to make a decision for or against IMGG as if they were the only ones it happened to is the right way to see it now. Imgg was not alone back then since many companies were handled the same way by those previous reviewers.
What matters now is what got submitted and resubmitted this year. If there are problems with this set of submissions, I might agree with you. But not yet.
Maybe Wharton only gave Dean $1,000,000 because that is all he requested.
I have never seen any magic tricks here at IMGG. If the FDA comes back with an SE approval, we will see much higher share price than the pessimistic .25 you are predicting. I do agree that an AI or NSE from FDA will hurt the IMGG share price. But most here are waiting on FDA SE so we can decide at what price to sell our shares as the buy out takes place.
I know I am here to make money. There is no other reason I am here. I hope that Dean and company can deliver. So do many others here.
PARDON ME SIR, BUT I THINK YOUR GOLD HAS ARRIVED!